This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-21. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
Laboratory samples of SR9009 are typically handled as research chemicals rather than pharmaceuticals. Suppliers usually state that the material is for research use only and not for human or veterinary administration. Storage recommendations generally call for a freezer at approximately −20 °C, protection from light, and a desiccated environment. The solid is often described as a white to off-white powder. Solubility is commonly reported in organic solvents such as dimethyl sulfoxide and ethanol, with low solubility in water.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
=== Synthesis === One of the earliest syntheses of DMPEA (then referred to as "homoveratrylamine") was that of Pictet and Finkelstein, who made it in a multi-step sequence starting from vanillin. A similar sequence was subsequently reported by Buck and Perkin, as follows:
As a small open economy, Denmark is very dependent on its foreign trade. In 2017, the value of total exports of goods and services made up 55% of GDP, whereas the value of total imports amounted to 47% of GDP. Trade in goods made up slightly more than 60% of both exports and imports, and trade in services the remaining close to 40%. Machinery, chemicals and related products like medicine and agricultural products were the largest groups of export goods in 2017. Service exports were dominated by freight sea transport services from the Danish merchant navy. Most of Denmark's most important trading partners are neighbouring countries. The five main importers of Danish goods and services in 2017 were Germany, Sweden, United Kingdom, United States and Norway. The five countries from which Denmark imported most goods and services in 2017 were Germany, Sweden, the Netherlands, China and United Kingdom. After having almost consistently an external balance of payments current account deficit since the beginning of the 1960s, Denmark has maintained a surplus on its BOP current account for every year since 1990, with the single exception of 1998. In 2017, the current account surplus amounted to approximately 8% of GDP. Consequently, Denmark has changed from a net debtor to a net creditor country. By 1 July 2018, the net foreign wealth or net international investment position of Denmark was equal to 64.6% of GDP, Denmark thus having the largest net foreign wealth relative to GDP of any EU country.
=== Need for stoichiometric control === There are two important aspects with regard to the control of molecular weight in polymerization. In the synthesis of polymers, one is usually interested in obtaining a product of very specific molecular weight, since the properties of the polymer will usually be highly dependent on molecular weight. Molecular weights higher or lower than the desired weight are equally undesirable. Since the degree of polymerization is a function of reaction time, the desired molecular weight can be obtained by quenching the reaction at the appropriate time. However, the polymer obtained in this manner is unstable, in that it leads to changes in molecular weight because the ends of the polymer molecule contain functional groups that can react further with each other. This situation is avoided by adjusting the concentrations of the two monomers so that they are slightly nonstoichiometric. One of the reactants is present in slight excess. The polymerization then proceeds to a point at which one reactant is completely used up and all the chain ends possess the same functional group of the group that is in excess. Further polymerization is not possible, and the polymer is stable to subsequent molecular-weight changes. Another method of achieving the desired molecular weight is by addition of a small amount of monofunctional monomer, a monomer with only one functional group.
17 July – Members of Unison at 14 Scottish council areas, including Glasgow, Perth and Kinross and Dumfries and Galloway, vote to take industrial action after describing a pay offer from COSLA as "inadequate". 19 July – Unison rejects the latest offer from Cosla aimed at preventing strikes by refuse collectors, which was worth 3.2%. 21 July – Data from Public Health Scotland for the week ending 14 July indicates there were 1,130 cases of COVID-19 in Scotland, but the health body believes cases may have peaked. 22 July – Following the death of 17-year-old Jonathan Beadle at Polmont Young Offenders Institution on Saturday 13 July, the Scottish Government announces that nobody under the age of 18 will be kept in prison in Scotland from the week beginning 2 September. Unite and the GMB follow Unison in rejecting the latest pay offer for refuse workers from Cosla. 23 July – The family of Allan Marshall, who died after being restrained by 17 prison officers at HMP Edinburgh in 2015, are to sue the Scottish Government under human rights legislation in what is believed to be the first case of its kind. 24 July – Researchers from the Scottish Association for Marine Science report evidence of dark oxygen being produced from manganese nodules on the seafloor. It was previously assumed that almost all the free oxygen (O2) on Earth was created through photosynthesis, which requires sunlight. The research has since come under criticism for methodological and ethical issues.
Sources: en.wikipedia.org
PMID 1116247. Daly, M.M. (January 1976). "Effects of age and hypertension on utilization of glucose by rat aorta". American Journal of Physiology. 230 (1): 30–33. doi:10.1152/ajplegacy.1976.230.1.30. PMID 1251907. Park, Sung Suh; Kikkawa, Yutaka; Goldring, Irene P.; Daly, Marie M.; Zelefsky, Melvin; Shim, Chang; Spierer, Morris; Morita, Toyohiko (June 1, 1977). "An Animal Model of Cigarette Smoking in Beagle Dogs Correlative Evaluation of Effects on Pulmonary Function, Defense, and Morphology". American Review of Respiratory Disease. 115 (6): 971–979. doi:10.1164/arrd.1977.115.6.971 (inactive 12 July 2025). PMID 262108. Retrieved 8 November 2018.{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link) Daly, Marie M.; Seifter, Sam (August 1980). "Uptake of creatine by cultured cells". Archives of Biochemistry and Biophysics. 203 (1): 317–324. doi:10.1016/0003-9861(80)90182-4. PMID 7406503. Daly, Marie M. (February 1, 1985). "Guanidinoacetate methyltransferase activity in tissues and cultured cells". Archives of Biochemistry and Biophysics. 236 (2): 576–584. doi:10.1016/0003-9861(85)90661-7. PMID 3970526.
== Overdose == Overdoses of hydroxychloroquine are extremely rare, but extremely toxic. Eight people are known to have overdosed since the drug's introduction in the mid-1950s, of which three have died. Chloroquine has a risk of death in overdose in adults of about 20%, while hydroxychloroquine is estimated to be two or threefold less toxic. Serious signs and symptoms of overdose generally occur within an hour of ingestion. These may include sleepiness, vision changes, seizures, coma, stopping of breathing, and heart problems such as ventricular fibrillation and low blood pressure. Loss of vision may be permanent. Low blood potassium, to levels of 1 to 2 mmol/L, may also occur. Cardiovascular abnormalities such as QRS complex widening and QT interval prolongation may also occur. Treatment recommendations include early mechanical ventilation, heart monitoring, and activated charcoal. Supportive treatment with intravenous fluids and vasopressors may be required with epinephrine being the vasopressor of choice. Stomach pumping may also be used. Sodium bicarbonate and hypertonic saline may be used in cases of severe QRS complex widening. Seizures may be treated with benzodiazepines. Intravenous potassium chloride may be required, however this may result in high blood potassium later in the course of the disease. Dialysis does not appear to be useful.
Systemic Lupus Erythematosus (SLE) Systemic Sclerosis (SS) Primary Sjögren's Syndrome (pSS) Raynaud's phenomenon Scleroderma Rheumatoid Arthritis The addition of anti-U1 RNP antibodies reveals that many autoimmune diseases share symptoms such as joint pain, fatigue, and Raynaud's phenomenon. The pathogenic role of anti-nRNP antibodies in these diseases varies, and their presence may only reflect immune system deregulation rather than being the direct cause of disease symptoms. Yet, they have served as valuable biomarkers.
Sources: en.wikipedia.org
"In 1990 members of the Bush administration ... cited Security Council resolutions as sufficient support for the President to act militarily against Iraq without congressional authority." A series of UN Security Council resolutions and Arab League resolutions were passed regarding Iraq's invasion of Kuwait. Resolution 678, passed on 29 November 1990, gave Iraq a withdrawal deadline until 15 January 1991 and authorized "all necessary means to uphold and implement Resolution 660", and a diplomatic formulation authorizing the use of force if Iraq failed to comply. To ensure the US received economic backing, James Baker went on an 11-day journey to nine countries in September 1990, which the press dubbed "The Tin Cup Trip". The first stop was Saudi Arabia, which had already granted permission to the US to use its facilities. Baker believed that Saudi Arabia should assume some of the cost of to defend it. When Baker asked King Fahd for $15 billion, the King agreed, with the promise that Baker ask Kuwait for the same amount. The next day, 7 September, Baker did just that, and the emir of Kuwait, displaced in a Sheraton hotel outside Kuwait, agreed. Baker moved to enter talks with Egypt, whose leadership he considered "the moderate voice of the Middle East". President Mubarak was furious with Saddam for his invasion, and that Saddam had assured Mubarak that an invasion was not his intention. Egypt received approximately $7 billion in debt forgiveness for providing support and troops for the US-led intervention.
Among numerous advances in experimental techniques he has developed experimental methods for using DNA microarrays to investigate the basic principles of genome organization. Member Natl. Acad. Sci. USA. Thomas Bruice (1925–2019). American bioorganic chemist at UC Santa Barbara, pioneering researcher in chemical biology. Member Natl. Acad. Sci. USA.
=== Energy intensity === The langley (symbol Ly) is used to measure solar radiation or insolation. It is equal to one thermochemical calorie per square centimetre (4.184×104 J/m2 or ≈3.684 BTU/sq ft) and was named after Samuel Pierpont Langley. Its symbol should not be confused with that for the light-year, ly.
Alternatively, if the desired aptamer function is in vivo protein or whole cell binding for potential therapeutic or diagnostic application, incubation buffer conditions similar to in vivo plasma salt concentrations and homeostatic temperatures are more likely to generate aptamers that can bind in vivo. Another consideration in incubation buffer conditions is non-specific competitors. If there is a high likelihood of non-specific oligonucleotide retention in the reaction conditions, non specific competitors, which are small molecules or polymers other than the SELEX library that have similar physical properties to the library oligonucleotides, can be used to occupy these non-specific binding sites. Varying the relative concentration of target and oligonucleotides can also affect properties of the selected aptamers. If a good binding affinity for the selected aptamer is not a concern, then an excess of target can be used to increase the probability that at least some sequences will bind during incubation and be retained. However, this provides no selective pressure for high binding affinity, which requires the oligonucleotide library to be in excess so that there is competition between unique sequences for available specific binding sites.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.